2024-10-09 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, diagnostic tests, nutritional products, and branded generic pharmaceuticals.

**Performance Summary:**

1. **Relative Performance:**
   * ABT's cumulative return is 101.67%, while the S&P 500 (VOO) has returned 133.14%.
   * This indicates ABT has underperformed the market by **-31.47%**.
   * The relative underperformance places ABT at the **11.58th percentile** of its historical performance against the S&P 500.

2. **Recent Price Movement:**
   * Closing Price: 112.64
   * 5-Day Moving Average: 113.22
   * 20-Day Moving Average: 114.67
   * 60-Day Moving Average: 110.79
   * ABT's price is currently below its 5-day, 20-day, and 60-day moving averages, indicating a **short-term downtrend**.

3. **Technical Indicators:**
   * RSI: 28.11 (below 30, indicating **oversold conditions**)
   * PPO: -0.39 (negative, suggesting **potential for further downward movement**)
   * **Delta_Previous_Relative_Divergence:** -11.95 (negative, indicating **short-term downward pressure**)
   * **Expected Return:** 0.0% (over 5 years, relative to S&P 500)

4. **Recent Earnings and Outlook:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-07-31 | 0.74 | 10.38 B$     |
| 2024-05-02 | 0.7  | 9.96 B$      |
| 2023-11-01 | 0.82 | 10.14 B$     |
| 2023-08-03 | 0.79 | 9.98 B$      |
| 2024-07-31 | 0.79 | 9.98 B$      |

* Abbott's most recent earnings report (2024-07-31) shows that the company beat analysts' EPS estimates by 1%. 
* Revenue was slightly above expectations, but growth has been slowing down in recent quarters.
* Analysts are generally optimistic about Abbott's long-term prospects, citing the company's diverse product portfolio and strong market position.

5. **News and Recent Issues:**

* **Recent Market Outlook:** Market sentiment towards ABT remains positive.
* **Analyst Opinions:** Most analysts rate ABT a "Buy" or "Hold," with a 12-month price target ranging from $120 to $135.
* **Performance Highlights:** Abbott's recent performance has been impacted by factors such as supply chain disruptions, inflation, and rising interest rates. However, the company continues to invest in research and development, and is expected to benefit from growing demand for its products in emerging markets.

**Overall Analysis:**

Abbott Laboratories is a fundamentally sound company with a strong market position. However, the stock has recently underperformed the broader market, and technical indicators suggest potential for further downward movement in the short term. The company's recent earnings report showed modest growth and beat analysts' expectations, but investors are concerned about slowing growth in the coming quarters. Despite these challenges, ABT remains a long-term investment option for those looking for exposure to the healthcare sector. 

**Recommendation:** While the stock may be currently attractive at its current price, consider a wait-and-see approach before initiating a position. Monitor the company's upcoming earnings reports and industry trends for further insights.
